ストックスクリーナーアプリを入手
29.51
1.06%
0.31
アフターアワーズ：
29.54
0.03
+0.10%
前日終値:
$29.20
開ける：
$28.76
24時間の取引高:
630.04K
Relative Volume:
0.80
時価総額：
$1.86B
収益：
$10.00M
当期純損益:
$-425.15M
株価収益率:
-3.2441
EPS:
-9.0964
ネットキャッシュフロー:
$-210.48M
1週間 パフォーマンス:
-9.00%
1か月 パフォーマンス:
+2.54%
6か月 パフォーマンス:
+11.78%
1年 パフォーマンス:
+76.07%
1日の値動き範囲:
$28.16
$30.31
1週間の範囲:
$27.81
$32.97
52週間の値動き範囲:
$13.50
$44.60
Zenas Biopharma Inc Stock (ZBIO) Company Profile
名前
Zenas Biopharma Inc
セクター
電話
857-271-2954
住所
852 WINTER STREET, SUITE 250, WALTHAM
Compare ZBIO vs VRTX, REGN, ARGX, RVMD, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ZBIO
Zenas Biopharma Inc
|
29.51 | 1.98B | 10.00M | -425.15M | -210.48M | -9.0964 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Zenas Biopharma Inc Stock (ZBIO) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-01-05 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2025-03-20 | 開始されました | Wedbush | Outperform |
| 2025-02-04 | 開始されました | Wolfe Research | Outperform |
| 2024-12-16 | 開始されました | H.C. Wainwright | Buy |
| 2024-11-05 | 開始されました | Rodman & Renshaw | Buy |
| 2024-10-08 | 開始されました | Citigroup | Buy |
| 2024-10-08 | 開始されました | Guggenheim | Buy |
| 2024-10-08 | 開始されました | Jefferies | Buy |
| 2024-10-08 | 開始されました | Morgan Stanley | Overweight |
すべてを表示
Zenas Biopharma Inc (ZBIO) 最新ニュース
Walleye Capital LLC Takes $5.31 Million Position in Zenas BioPharma, Inc. $ZBIO - MarketBeat
Zenas BioPharma's (ZBIO) Buy Rating Reaffirmed at Guggenheim - MarketBeat
Zenas BioPharma's (ZBIO) Outperform Rating Reiterated at Wedbush - MarketBeat
Zenas BioPharma (ZBIO) Is Down 9.2% After Wider Losses And Leadership ChangesWhat's Changed - simplywall.st
ZBIO SWOT Analysis: Financial Challenges and Strategic Opportuni - GuruFocus
Zenas BioPharma (NASDAQ:ZBIO) Issues Earnings Results - MarketBeat
Zenas BioPharma Releases Q2 2026 Financial Results - AlphaStreet
Zenas BioPharma, Inc. Announces Chief Financial Officer Changes, Effective September 30, 2026 - marketscreener.com
Zenas BioPharma (NASDAQ:ZBIO) Stock Price Down 6.6% on Disappointing Earnings - MarketBeat
Zenas BioPharma Q2 Results: EPS Misses, Sales Fall 95% - scanx.trade
Zenas BioPharma, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Zenas BioPharma's Q2 Net Loss Widens; CFO to Step Down - marketscreener.com
Earnings Flash (ZBIO) Zenas BioPharma Posts Q2 Loss $1.77 a Share, vs. FactSet Est of $1.12 Loss - marketscreener.com
Form 8K Zenas Biopharma Inc For: 13 August By Investing.com - Investing.com South Africa
Zenas BioPharma, Inc. 2026: Revenue $1M, Net income ($111.46M), EPS ($1.77) — 10-Q Summary - TradingView
Zenas BioPharma Reports Second Quarter 2026 Financial Results and Provides Corporate Update - The Manila Times
Earnings Flash (ZBIO) Zenas BioPharma, Inc. Reports Q2 Revenue $1.0M - marketscreener.com
Zenas BioPharma Reports $111.5 Million Second-Quarter Net Loss - Quiver Quantitative
Zenas BioPharma (ZBIO) Holds Gains Above $32 as Bullish Momentum BuildsIndex Put Call - dars.gov.et
ZBIO LAWSUIT ALERT: Levi & Korsinsky Notifies Zenas BioPharma, In - The National Law Review
Zenas BioPharma, Inc. (ZBIO): Investor Outlook On A Potential 35% Upside - DirectorsTalk Interviews
Zenas BioPharma (ZBIO) Institutional Ownership 2026 - MarketBeat
Zenas Biopharma Inc (ZBIO) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Bronstein, Gewirtz & Grossman, LLC Encourages Zenas BioPharma, In - The National Law Review
Zenas BioPharma (ZBIO) Projected to Release Quarterly Earnings on Tuesday - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review
Levi & Korsinsky Urges Zenas BioPharma, Inc. (ZBIO) Shareholders to Act Before Lead Plaintiff Deadline June 16, 2025 - The National Law Review
Zenas Biopharma Inc (ZBIO) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Zenas BioPharma, Inc. (NASDAQ:ZBIO) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Exome Asset Management LLC Takes Position in Zenas BioPharma, Inc. $ZBIO - MarketBeat
Zenas Biopharma Inc (ZBIO) Balance Sheet - TradingKey
Zenas Biopharma Inc (ZBIO) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Zenas Biopharma Inc (ZBIO) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Zenas Biopharma Inc (ZBIO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Zenas BioPharma (NASDAQ:ZBIO) Trading 7.7% HigherStill a Buy? - MarketBeat
ZBIO|Zenas Biopharma Inc|Price:30.390|Chg%:-0.600 - TradingKey
Zenas Biopharma Inc (ZBIO) Valuation: PE, PB & Fair Value Analysis - TradingKey
TradingKey - TradingKey
Securities Lawsuit Alert: Zenas BioPharma, Inc. (ZBIO) Investors - The National Law Review
125,232 Shares in Zenas BioPharma, Inc. $ZBIO Bought by Walleye Capital LLC - MarketBeat
Zenas BioPharma (ZBIO) Dips 2.7% as Resistance Holds: Key Levels to WatchSeasonality Effect - dars.gov.et
Jennison Associates LLC Buys Shares of 250,000 Zenas BioPharma, Inc. $ZBIO - MarketBeat
ZBIO6353884 Bond Profile — Key Metrics - TradingView
ZBIO6353884 Bond Risk Profile - TradingView
ZBIO6353884 Bond Coupon Profile — Rate & Payments - TradingView
Zenas BioPharma (ZBIO) Gains Nearly 4% as Biotech Momentum BuildsBackspread Trade - dars.gov.et
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Zenas BioPharma Bear Case Overlooks Obexelimab's Commercial Potential, Wedbush Says - Moomoo
Zenas BioPharma Grants Inducement Stock Options and RSUs to New Employees - Quiver Quantitative
Zenas BioPharma, Inc. (ZBIO) Investigation: Bronstein, Gewirtz - The National Law Review
Zenas BioPharma shows promising Phase 3 results for autoimmune drug obexelimab, boosting growth outlook. - Pluang
Zenas Biopharma Inc (ZBIO) 財務データ
収益
当期純利益
現金流量
EPS
0.52%
0.07%
大文字化:
|
ボリューム (24 時間):